Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2/3 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Breast 3Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Dermatologic 1

Conditions

Breast Neoplasms 3Neurotoxicity Syndromes 1Heart Failure 1Cardiotoxicity 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carnitine × Breast × Clear all
NCT00247975 2022-08-16

Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Ottawa Heart Institute Research Corporation

Phase 2/3 Terminated
36 enrolled
Breast

Breast Neoplasms, Heart Failure

NCT04434404 2020-06-16

Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy

Horus University

Phase 4 Completed
83 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT00754767 2017-09-11

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

HealthPartners Institute

Phase 4 Terminated
2 enrolled 3 charts
Breast

Breast Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡